GeneDx CEO Katherine Stueland Named to TIME100 Health List 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy WGS?
Source: Newsfilter
- Leadership Recognition: GeneDx CEO Katherine Stueland has been named to the 2026 TIME100 Health list, highlighting her influence in global health, particularly in rare disease diagnosis, which enhances the company's significance in the healthcare ecosystem.
- Genomics Advancement: Under Stueland's leadership, GeneDx has built the world's largest rare disease genomic dataset, GeneDx Infinity™, which helps reduce the average diagnostic odyssey of over five years for families, thereby improving health outcomes for patients and families and emphasizing the importance of genomics in modern medicine.
- Public Health Initiatives: GeneDx is involved in several public-private partnerships, such as the GUARDIAN study and Florida's Sunshine Genetics Program, showcasing the potential of genomics in newborn screening, with the aim of reducing rare disease diagnosis time from years to days, shifting healthcare from reactive to proactive.
- FDA Breakthrough Device Designation: GeneDx received FDA Breakthrough Device Designation for its exome and genome testing, indicating its effectiveness in diagnosing life-threatening diseases, and the American Academy of Pediatrics' updated guidelines further promote early diagnosis and informed clinical decision-making for children.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 90.670
Low
155.00
Averages
171.43
High
200.00
Current: 90.670
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GeneDx CEO Katherine Stueland Named to TIME100 Health List 2026
- Leadership Recognition: GeneDx CEO Katherine Stueland has been named to the 2026 TIME100 Health list, highlighting her influence in global health, particularly in rare disease diagnosis, which enhances the company's significance in the healthcare ecosystem.
- Genomics Advancement: Under Stueland's leadership, GeneDx has built the world's largest rare disease genomic dataset, GeneDx Infinity™, which helps reduce the average diagnostic odyssey of over five years for families, thereby improving health outcomes for patients and families and emphasizing the importance of genomics in modern medicine.
- Public Health Initiatives: GeneDx is involved in several public-private partnerships, such as the GUARDIAN study and Florida's Sunshine Genetics Program, showcasing the potential of genomics in newborn screening, with the aim of reducing rare disease diagnosis time from years to days, shifting healthcare from reactive to proactive.
- FDA Breakthrough Device Designation: GeneDx received FDA Breakthrough Device Designation for its exome and genome testing, indicating its effectiveness in diagnosing life-threatening diseases, and the American Academy of Pediatrics' updated guidelines further promote early diagnosis and informed clinical decision-making for children.
See More
Global Payments Inc (GPN) Options Trading Volume Hits 1.6 Million Shares
- Active Options Trading: Global Payments Inc (GPN) saw options trading volume of 16,123 contracts today, representing approximately 1.6 million shares, which is about 53% of its average daily trading volume of 3 million shares over the past month, indicating strong market interest in its future performance.
- High Volume Analysis: Notably, the $60 strike put option for GPN has seen particularly high activity with 7,070 contracts traded today, representing around 707,000 underlying shares, reflecting investor expectations regarding potential downside risks for the stock.
- GeneDx Options Activity: Concurrently, GeneDx Holdings Corp (WGS) has recorded an options trading volume of 2,883 contracts today, equivalent to approximately 288,300 shares, which constitutes 52% of its average daily trading volume of 554,545 shares over the past month, indicating investor focus on its market performance.
- Bullish Call Option Trend: For WGS, the $150 strike call option has seen a trading volume of 1,512 contracts today, representing about 151,200 shares, suggesting a bullish outlook among investors regarding its future price potential.
See More
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
- AI Infrastructure Boost: ARK Invest increased positions in semiconductor companies like AMD, Broadcom, and TSMC, signaling strong confidence in the infrastructure for AI workloads, which is expected to drive long-term growth for these firms.
- Gene Editing Investments: The firm added 196K shares of Intellia Therapeutics and 49K shares of 10x Genomics, continuing to focus on next-generation sequencing and in vivo gene editing, aiming to capture innovative opportunities in the biotech sector.
- Autonomous Driving Focus: ARK invested in companies like WeRide and Pony AI in the autonomous driving and robotics space, reinforcing its strategic positioning in future transportation technologies, which is likely to enhance portfolio diversity and potential returns.
- Trimmed Mature Tech Holdings: ARK sold over 86K shares of Tesla worth more than $37 million and reduced stakes in Unity Software, reflecting a cautious stance on mature tech companies that may impact short-term stock performance.
See More
GeneDx Holdings Corp (WGS) Options Volume Hits 4,198 Contracts, 109.9% of Average
- Active Options Trading: GeneDx Holdings Corp's options volume reached 4,198 contracts today, representing approximately 419,800 underlying shares, indicating a trading activity level of 109.9% of its average daily volume over the past month.
- Put Option Focus: Notably, the $100 strike put option expiring on February 20, 2026, saw 705 contracts traded today, representing about 70,500 underlying shares, reflecting market attention at this price level.
- Alphabet Options Activity: Concurrently, Alphabet Inc's options trading volume stood at 320,179 contracts, equivalent to approximately 32.0 million underlying shares, reaching 108.8% of its average daily volume over the past month, indicating strong market engagement.
- High Interest Call Option: Among Alphabet's options, the $330 strike call option expiring on January 16, 2026, recorded a trading volume of 23,994 contracts, representing around 2.4 million underlying shares, suggesting investor expectations for future price increases.
See More
GeneDx Reports $427M Revenue for 2025, 41% YoY Growth
- Significant Revenue Growth: GeneDx reported approximately $427M in revenue for 2025, aligning with market expectations and reflecting a 41% year-over-year increase, which reinforces the company's strong position in the genetic testing market.
- Robust Genomic Revenue: The exome and genome revenue for 2025 reached approximately $360M, marking a 54% year-over-year growth, exceeding prior guidance of 53% to 55%, indicating sustained expansion in high-growth areas.
- Increased Test Volume: The total volume of exome and genome test results for 2025 was 97,271, representing a 30.5% year-over-year increase, surpassing the company's prior guidance of at least 30%, reflecting strong customer demand recovery.
- Optimistic Future Outlook: GeneDx anticipates revenue for 2026 to be between $540M and $555M, with exome and genome revenue expected to grow by 33% to 35%, demonstrating the company's confidence in future growth and a positive market outlook.
See More
GeneDx Partners with Komodo Health to Build Comprehensive Rare Disease Dataset
- Strategic Partnership: GeneDx has formed a strategic partnership with Komodo Health to leverage Komodo's Healthcare Map®, creating the most comprehensive longitudinal dataset for rare diseases, enhancing visibility into diagnosis, management, and treatment.
- Data Scale: GeneDx Infinity™ is the world's largest rare disease genomic dataset, built on over 2.5 million genetic tests and more than 7 million phenotypic data points, with over half of individuals representing non-European ancestry, showcasing exceptional diversity and representation.
- Accelerating Innovation: This collaboration is set to drive biopharma innovation, with GeneDx Infinity expected to generate 30% more exome and genome data in 2025 than in the previous 24 years combined, providing a richer evidence base for rare disease research.
- Privacy Protection: All data integrations and analyses will utilize de-identified, privacy-preserving methodologies to ensure regulatory compliance and protect patient confidentiality, thereby maintaining ethical standards while advancing research.
See More
GeneDx CEO Katherine Stueland Named to TIME100 Health List 2026
- Leadership Recognition: GeneDx CEO Katherine Stueland has been named to the 2026 TIME100 Health list, highlighting her influence in global health, particularly in rare disease diagnosis, which enhances the company's significance in the healthcare ecosystem.
- Genomics Advancement: Under Stueland's leadership, GeneDx has built the world's largest rare disease genomic dataset, GeneDx Infinity™, which helps reduce the average diagnostic odyssey of over five years for families, thereby improving health outcomes for patients and families and emphasizing the importance of genomics in modern medicine.
- Public Health Initiatives: GeneDx is involved in several public-private partnerships, such as the GUARDIAN study and Florida's Sunshine Genetics Program, showcasing the potential of genomics in newborn screening, with the aim of reducing rare disease diagnosis time from years to days, shifting healthcare from reactive to proactive.
- FDA Breakthrough Device Designation: GeneDx received FDA Breakthrough Device Designation for its exome and genome testing, indicating its effectiveness in diagnosing life-threatening diseases, and the American Academy of Pediatrics' updated guidelines further promote early diagnosis and informed clinical decision-making for children.
See More
Global Payments Inc (GPN) Options Trading Volume Hits 1.6 Million Shares
- Active Options Trading: Global Payments Inc (GPN) saw options trading volume of 16,123 contracts today, representing approximately 1.6 million shares, which is about 53% of its average daily trading volume of 3 million shares over the past month, indicating strong market interest in its future performance.
- High Volume Analysis: Notably, the $60 strike put option for GPN has seen particularly high activity with 7,070 contracts traded today, representing around 707,000 underlying shares, reflecting investor expectations regarding potential downside risks for the stock.
- GeneDx Options Activity: Concurrently, GeneDx Holdings Corp (WGS) has recorded an options trading volume of 2,883 contracts today, equivalent to approximately 288,300 shares, which constitutes 52% of its average daily trading volume of 554,545 shares over the past month, indicating investor focus on its market performance.
- Bullish Call Option Trend: For WGS, the $150 strike call option has seen a trading volume of 1,512 contracts today, representing about 151,200 shares, suggesting a bullish outlook among investors regarding its future price potential.
See More
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
- AI Infrastructure Boost: ARK Invest increased positions in semiconductor companies like AMD, Broadcom, and TSMC, signaling strong confidence in the infrastructure for AI workloads, which is expected to drive long-term growth for these firms.
- Gene Editing Investments: The firm added 196K shares of Intellia Therapeutics and 49K shares of 10x Genomics, continuing to focus on next-generation sequencing and in vivo gene editing, aiming to capture innovative opportunities in the biotech sector.
- Autonomous Driving Focus: ARK invested in companies like WeRide and Pony AI in the autonomous driving and robotics space, reinforcing its strategic positioning in future transportation technologies, which is likely to enhance portfolio diversity and potential returns.
- Trimmed Mature Tech Holdings: ARK sold over 86K shares of Tesla worth more than $37 million and reduced stakes in Unity Software, reflecting a cautious stance on mature tech companies that may impact short-term stock performance.
See More
GeneDx Holdings Corp (WGS) Options Volume Hits 4,198 Contracts, 109.9% of Average
- Active Options Trading: GeneDx Holdings Corp's options volume reached 4,198 contracts today, representing approximately 419,800 underlying shares, indicating a trading activity level of 109.9% of its average daily volume over the past month.
- Put Option Focus: Notably, the $100 strike put option expiring on February 20, 2026, saw 705 contracts traded today, representing about 70,500 underlying shares, reflecting market attention at this price level.
- Alphabet Options Activity: Concurrently, Alphabet Inc's options trading volume stood at 320,179 contracts, equivalent to approximately 32.0 million underlying shares, reaching 108.8% of its average daily volume over the past month, indicating strong market engagement.
- High Interest Call Option: Among Alphabet's options, the $330 strike call option expiring on January 16, 2026, recorded a trading volume of 23,994 contracts, representing around 2.4 million underlying shares, suggesting investor expectations for future price increases.
See More
GeneDx Reports $427M Revenue for 2025, 41% YoY Growth
- Significant Revenue Growth: GeneDx reported approximately $427M in revenue for 2025, aligning with market expectations and reflecting a 41% year-over-year increase, which reinforces the company's strong position in the genetic testing market.
- Robust Genomic Revenue: The exome and genome revenue for 2025 reached approximately $360M, marking a 54% year-over-year growth, exceeding prior guidance of 53% to 55%, indicating sustained expansion in high-growth areas.
- Increased Test Volume: The total volume of exome and genome test results for 2025 was 97,271, representing a 30.5% year-over-year increase, surpassing the company's prior guidance of at least 30%, reflecting strong customer demand recovery.
- Optimistic Future Outlook: GeneDx anticipates revenue for 2026 to be between $540M and $555M, with exome and genome revenue expected to grow by 33% to 35%, demonstrating the company's confidence in future growth and a positive market outlook.
See More
GeneDx Partners with Komodo Health to Build Comprehensive Rare Disease Dataset
- Strategic Partnership: GeneDx has formed a strategic partnership with Komodo Health to leverage Komodo's Healthcare Map®, creating the most comprehensive longitudinal dataset for rare diseases, enhancing visibility into diagnosis, management, and treatment.
- Data Scale: GeneDx Infinity™ is the world's largest rare disease genomic dataset, built on over 2.5 million genetic tests and more than 7 million phenotypic data points, with over half of individuals representing non-European ancestry, showcasing exceptional diversity and representation.
- Accelerating Innovation: This collaboration is set to drive biopharma innovation, with GeneDx Infinity expected to generate 30% more exome and genome data in 2025 than in the previous 24 years combined, providing a richer evidence base for rare disease research.
- Privacy Protection: All data integrations and analyses will utilize de-identified, privacy-preserving methodologies to ensure regulatory compliance and protect patient confidentiality, thereby maintaining ethical standards while advancing research.
See More
